Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGASYS + Copegus in Genotype 1 CHC Non-responders
NCT00412334Phase 4Completed
- Sponsor
- Roche
- Start
- Jan 2007
- Primary completion
- Sep 2010
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C (HCV) (4 arms), sponsored by Roche. Primary endpoint: Sustained Viral Response at 72 weeks. Started Jan 2007; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00412334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412334.